$Royalty Pharma (RPRX.US)$Over the past 5 years, revenue has...
$Royalty Pharma (RPRX.US)$Over the past 5 years, revenue has maintained a moderate growth, increasing from 1.6 billion to 2.3 billion. However, operating profit has skyrocketed by 92% in 2019 to reach 2.6 billion, but has been declining for the past 2 years to 1.43 billion. This is mainly due to other operating expenses. Net income follows a similar trend as operating profit and fell to 1.24 billion in 2021.
In the first three quarters of 2022, revenue declined by 2.5%, operating profit declined by 38%, and net income declined by 29% to 0.84 billion. After deducting minority shareholders' net income of 3.4, it is only 0.5 billion attributable to common shareholders, a year-on-year decrease of 18.5%.
The current P/E ratio is 26.4 and the P/E ratio TTM is 34.5, which is not very attractive.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
